Shares in Moderna more than tripled this year, as investors piled into the stock amid hopes for the potential of its virus vaccine. It looks like the rally has not yet run out of steam. Indeed, the $87.64 average analyst price target still indicates a bullish 43% upside potential from current levels. ( See Moderna stock analysis on TipRanks ).